Start Time: 08:30 January 1, 0000 9:18 AM ET

Viking Therapeutics, Inc. (NASDAQ:VKTX)

Q4 2023 Earnings Conference Call

February 07, 2024, 16:30 PM ET

Company Participants

Brian Lian - President and CEO

Greg Zante - CFO

Stephanie Diaz - Manager of IR

Conference Call Participants

Joon Lee - Truist

Steven Seedhouse - Raymond James

Jay Olson - Oppenheimer.

Naz Rahman - Maxim Group.

Andy Hsieh - William Blair.

Thomas Smith - Leerink Partners.

Yale Jen - Laidlaw & Company.

Joe Pantginis - HC Wainwright.

Jack Padovano - Stifel.

Justin Zelin - BTIG.

Operator

Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a question-and-answer session. [Operator Instructions]. As a reminder, this conference call is being recorded today, February 7, 2024.

I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead.

Stephanie Diaz

Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO.

Before we begin, I'd like to caution that comments made during this conference call today, February 7, 2024, will contain forward-looking statements under the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance.

These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission, concerning these and other matters.

I'll now turn the call over to Brian Lian for his initial comments.

Brian Lian

Thanks, Stephanie, and good afternoon to everyone dialed in by phone or listening on the webcast. Today, we'll review our financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on recent progress with our clinical programs and operations. 2023 was an exciting year for Viking, highlighted by important data releases from two of our four clinical programs.

With respect to our obesity program, during the year, we announced positive results from a first-in-human Phase 1 clinical trial of VK2735, a dual agonist of the GLP-1 and GIP receptors. In this study, subjects dosed with VK2735 demonstrated statistically significant weight loss with favorable safety and tolerability.